Warsaw, July 16, 2020, a global contract research organisation, today announced the successful adoption of TheraSphere by the Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice branch (Centrum Onkologii - Instytut, im. Marii Skłodowskiej-Curie Gliwice), Poland.
Following the treatment within clinical trial patients in Poland with cancerous tumors in the liver will be evaluated for treatment suitability by the specialist cross-functional team of Oncologists, Interventional Radiologists, and Nuclear Medicine Physicians.
Wojciech Kula, VP Clinical Development of Clinscience commented “We are delighted to be collaborating with the team at Boston Scientific to enable broader access for patients to TheraSphere outside of clinical trials. My team and I look forward to our ongoing collaboration with all major oncology centers across Poland so that many more patients may derive benefit from access to TheraSphere.
Giuseppe Monita Head of EMEA Interventional Oncology Boston Scientific, mentioned “we are committed to working with our partners to offer treatment solutions that make a difference to physicians and their patients.
TheraSphere™ is a targeted therapy for the treatment of hepatic neoplasia that consists of millions of glass microspheres containing radioactive Y90. The microspheres are delivered directly to liver tumors through the hepatic artery via a catheter and become permanently lodged there. Because the procedure delivers the treatment directly to the liver tumor, the radiation destroys the tumor cells with minimal impact on the surrounding healthy liver tissue. The microspheres continue to deliver radiation to the tumor over the course of several weeks after treatment. Over 30,000 patients worldwide have been treated with TheraSphere™.
For full instructions for use and important safety information, please visit therasphere.eu
Clinscience is a global forward-thinking CRO that came into being by merging 2 successful CRO's - ClinMed Pharma and Bioscience.
We believe that what is most valuable in clinical research arises from the combination of knowledge, experience, the use of technology, and the involvement of people who want to create a healthier future.
Now we continue pursuing our mission as Clinscience and help our partners develop and conduct clinical trials, supporting the launch of new products that improve patients' expectancy and quality of life. We deliver meaningful value to our partners: pharmaceutical and biotechnology companies, scientific and research institutions, and start-ups by working together on the development of new molecules and innovative products.
We conduct phase I-IV clinical trials on new drugs and medical devices.
Get in touch via LinkedIn https://www.linkedin.com/company/clinscience360cro/
About Boston Scientific Interventional Oncology
Boston Scientific Interventional Oncology strives to develop ground-breaking technologies, administered using minimally-invasive, image-guided therapies. By specifically targeting diseased cells, we can limit the impact on healthy tissue and bring a significant quality of life benefits to patients.
Our portfolio of innovative products is used to treat and provide symptomatic relief for people with cancer and benign tumors. We provide high-value patient-centric treatment options which include locally-applied embolisation, radiotherapy with Y90 glass microspheres, and cryoablation. Modern medicine is evolving and at BTG Interventional Oncology, we believe that intelligent science is the way forward. Please follow @BTGIO on Twitter or visit btg-io.com.
CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France. 2020 Copyright © Boston Scientific Corporation or its affiliates. All rights reserved. PI- 840902-AA